Lebrikizumab Delivers Long-Term Atopic Dermatitis Control

Up to 4 years of sustained skin clearance and itch relief in moderate-to-severe cases

Mar. 30, 2026 at 7:20am

Got story updates? Submit your updates here. ›

In the ongoing ADlong Phase 3b study, 94% of patients with moderate-to-severe atopic dermatitis achieved meaningful skin improvement (EASI-75) with up to four years of lebrikizumab treatment. Additionally, 75% of patients achieved near-complete skin clearance (EASI-90) and 78% experienced meaningful itch relief (Pruritus NRS ≤4), reinforcing the long-term efficacy and safety of lebrikizumab in this patient population.

Why it matters

Long-term disease control is essential for managing the chronic, unpredictable nature of moderate-to-severe atopic dermatitis. These positive interim results from the ADlong study demonstrate lebrikizumab's potential to fundamentally improve quality of life for patients by providing sustained relief from both skin symptoms and debilitating itch over several years.

The details

In the ADlong study, the majority of patients achieved these outcomes without the need for topical corticosteroids or increased dosing frequency, highlighting lebrikizumab's ability to offer robust, long-term disease management. The safety profile of lebrikizumab remained consistent with previous studies, with no new safety signals observed.

  • The ADlong Phase 3b study is ongoing and will continue for an additional year of treatment.
  • The interim findings from the first year of the ADlong study were presented at the American Academy of Dermatology (AAD) Annual Meeting in March 2026.

The players

Almirall

A global biopharmaceutical company focused on medical dermatology that has licensed the rights to develop and commercialize lebrikizumab in Europe.

Prof Weidinger

From the University Medical Center Schleswig-Holstein, Department for Dermatology and Allergy, who commented on the importance of long-term efficacy in managing moderate-to-severe atopic dermatitis.

Karl Ziegelbauer

Chief Scientific Officer at Almirall, who highlighted the company's commitment to advancing skin science and improving patient outcomes.

Lebrikizumab

A monoclonal antibody that selectively targets the cytokine IL-13, blocking its downstream signaling while preserving IL-13 physiological clearance.

ADlong Study

An ongoing Phase 3b study evaluating the long-term safety and efficacy of lebrikizumab in patients with moderate-to-severe atopic dermatitis.

Got photos? Submit your photos here. ›

What they’re saying

“At Almirall, we are committed to advancing skin science with meaningful therapies that improve patients' lives. These interim data from the ADlong study further support the long-term value of lebrikizumab in treating patients with moderate-to-severe atopic dermatitis, highlighting its potential to fundamentally improve disease control and positively transform patients' quality of life.”

— Karl Ziegelbauer, Chief Scientific Officer at Almirall

“Long-term efficacy is essential in moderate-to-severe atopic dermatitis, a disease characterized by chronic inflammation and unpredictable flares. When a treatment can offer patients sustained control of both skin symptoms and itch over several years, it has the potential to transform daily life and redefine what we consider achievable in AD management.”

— Prof Weidinger, University Medical Center Schleswig-Holstein, Department for Dermatology and Allergy

What’s next

The ADlong study is ongoing and will continue for an additional year of treatment, with further results expected to be presented in the future.

The takeaway

These positive long-term results from the ADlong study demonstrate lebrikizumab's potential to provide sustained relief from the debilitating symptoms of moderate-to-severe atopic dermatitis, including skin inflammation and itch, over several years. This could significantly improve quality of life for patients living with this chronic, unpredictable condition.